Download App

Log in to access Online Inquiry
Company Overview More
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.
CEO: Barbier, Remi
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Moomoo > Quotes > SAVA Cassava Sciences > Detailed Quotes

SAVA Cassava Sciences

23.980+1.700+7.63%
Close 05/19 20:00 ET
24.200+0.22+0.92%
Pre Mkt Price 05/20 07:18 ET
High
24.090
Open
21.910
Turnover
20.60M
Low
21.910
Pre Close
22.280
Volume
876.68K
Market Cap
961.14M
P/E(TTM)
Loss
52wk High
146.160
Shares
40.08M
P/E(Static)
Loss
52wk Low
15.720
Float Cap
875.49M
Bid/Ask %
-33.33%
Historical High
146.160
Shs Float
36.51M
Volume Ratio
0.74
Historical Low
1.000
Dividend TTM
--
Div Yield TTM
--
P/B
4.05
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
2.40%
Amplitude
9.79%
Avg Price
23.492
Lot Size
1
Float Cap
875.49M
Bid/Ask %
-33.33%
Historical High
146.160
Shs Float
36.51M
Volume Ratio
0.74
Historical Low
1.000
Dividend TTM
--
P/B
4.05
Dividend LFY
--
Turnover Ratio
2.40%
Amplitude
9.79%
Avg Price
23.492
Lot Size
1
Price Forecast

No Data

News

Comment